Vaccitech Newsroom
News & updates
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Oxford, UK – Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has dosed the first person in a Phase 1 clinical study to investigate the safety and...
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being...
Oxford COVID-19 vaccine begins human trial stage
Oxford, UK - Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half...
Vaccitech to Present at Solebury Trout Virtual Investor Conference
Oxford, UK – 30th March 2020 Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company’s progress...
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Oxford, UK – Vaccitech Limited and the University of Oxford today announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in patients with metastatic castration resistant prostate cancer (mCRPC)....
Vacancy: Clinical Programme Lead
To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs in accordance with quality requirements,...
Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
Oxford, UK – Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat cancer and chronic infectious diseases, announces top line Phase 2 data and plans for its recombinant Modified Vaccinia Ankara (MVA) Universal Influenza A...
New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia
Vaccitech’s partner, the University of Oxford’s Jenner Institute, in collaboration with The King Abdullah International Medical Research Centre (KAIMRC), announced that it has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against...
Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
Oxford, UK – 18 December 2019: Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical partnership with Cancer Research UK to develop VOLT’s...
Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studies
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020 Oxford, United Kingdom – 25th November 2019: Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing...